

AUG 29 2003

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.
Substitute for form 1449/PTO

PTO.SB/08A (04-03)

Approved for use through 04/30/03. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICATION**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/631,358
Filing Date	July 30, 2003
First Named Inventor	David Kucera
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	PC19184 (AG0184)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	Cite No. ¹	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ²			
LH	AA	2002/0025976	02-28-2002	Agouron Pharmaceuticals, Inc.	
LH	AB	6,114,365	09-05-2000	Pharmacia & Upjohn S.P.A.	
LH	AC	6,262,096	07-17-2001	Bristol-Myers Squibb Company	
LH		10/190,219	N/A	Agouron Pharmaceuticals, Inc.	
LH		60/402,408	N/A	Agouron Pharmaceuticals, Inc.	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
LH	AD	WO 00/17175 ✓	03-30-2000	Vertex Pharmaceuticals Incorporated		
LH	AE	WO 00/26202 ✓	05-11-2000	Pharmacia & Upjohn S.P.A.		
LH	AF	WO 00/26203 ✓	05-11-2000	Pharmacia & Upjohn S.P.A.		
LH	AG	WO 00/75120	12-14-2000	Agouron Pharmaceuticals, Inc.		
LH	AH	WO 01/44241	06-21-2001	Bristol-Myers Squibb Co.		

EXAMINER:

DATE CONSIDERED:

11/1/05

EXAMINER: Initial if reference considered, whether or no citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901-04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Mail Stop: DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for Form 1449/PTO

Complete if Known

Application Number	10/631,358
Filing Date	July 30, 2003
First Named Inventor	David Kucera
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	PC19184 (AG0184)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICATION**

(Use as many sheets as necessary)

LH	AI	WO 01/44242	06-21-2001	Bristol-Myers Squibb Co.	
LH	AJ	WO 99/21845	05-06-1999	Agouron Pharmaceuticals, Inc.	
LH	AK	WO 99/24035	05-20-1999	Bristol-Myers Squibb Co.	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LH	AL	BAER, et al., "A Novel Solid-Phase Approach to 2,4-Diaminothiazoles" <i>J. Comb. Chem.</i> , 2001, pages 16-19, vol. 3.	
LH	AM	BINU, et al., "Synthesis and Cyclization of 1-(N-Nitroamidino)Thioureas to 2,4-Diaminothiazoles" <i>Org. Prep. Proced. Intl.</i> , 1998, pages 93-96, vol. 30.	
LH	AN	DEVI, et al., "Synthesis of 2, 4-Diamino-5-(FUR-2-OYL), (THIEN-2-OYL), and (PYRID-2-OYL) Thiazoles" <i>Syn. Comm.</i> , 2002, pages 1523-1528, vol. 32.	
LH	AO	FISHBEIN, et al., "Treatment of Restenosis by Controlled-Release Delivery System of Tyrophostins" <i>Drug Dev. Res.</i> , 2000, pages 487-496, vol. 50.	
LH	AP	GARCIA-ECHEVERRIA, et al., "ATP Site-Directed Competitive and Irreversible Inhibitors of Protein Kinases" <i>Med. Res. Rev.</i> , 1999, pages 28-57, vol. 20.	
LH	AQ	GEWALD, et al., "4-Amino-thiazole" <i>J. Prakt. Chem.</i> , 1967, pages 97-104, vol. 35.	
LH	AR	GRAY, et al., "ATP-Site Directed Inhibitors of Cyclin-dependent Kinases" <i>Curr. Med. Chem.</i> , 1999, pages 859-875, vol. 6.	
LH	AS	GRUDZINSKI, et al., "Synteza Pochodnych 1, 2-Dwuaminopropanu I. Otrzymywanie D, L-1-Dwumetyloamino-2-Aminopropanu" <i>Acta Pol. Pharm.</i> , 1976, pages 571-576, vol. 33.	
LH	AT	GUTHRIE, et al., "Carbanions. Electron Transfer vs. Proton Capture. 7. Electron-Transfer Oxidation of an Amino Acid Derived Carbanion" <i>J. Org. Chem.</i> , 1981, pages 498-501, vol. 46.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or no citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. ¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901-04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Mail Stop: DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

Complete if Known

Application Number	10/631,358
Filing Date	July 30, 2003
First Named Inventor	David Kucera
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	PC19184 (AG0184)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICATION**

(Use as many sheets as necessary)

LH	AU	ISOGAI, et al., "Structure of a Peptidal Antibiotic P168 produced by <i>Paecilomyces lilacinus</i> (Thom) Samson" <i>J. Chem. Soc. Perkin Trans.</i> , 1984, pages 1405-1411, vol. 1.	
LH	AV	JENARDANAN, et al., "1-(N-Arylthiocarbamoyl) Amidino-3, 5-Dimethyl Pyrazoles – Preparation and Use in Heterocycle Synthesis" <i>Syn. Comm.</i> , 1997, pages 3457-3462, vol. 27.	
LH	AW	KAMINSKI, et al., "2-Chloro-4,6-Dimethoxy-1,3,5-Triazine. A New Coupling Reagent for Peptide Synthesis" <i>Synthesis</i> , 1987, pages 917-920, vol. 20.	
LH	AX	KUNISHIMA, et al., "4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methyl-morpholinium Chloride: An Efficient Condensing Agent Leading to the Formation of Amides and Esters" <i>Tetrahedron</i> , 1999, pages 13159-13170, vol. 55.	
LH	AY	LI, et al., "An Improved Procedure for the Preparation of Isothiocyanates from Primary Amines by Using Hydrogen Peroxide as the Dehydrosulfurization Reagent" <i>J. Org. Chem.</i> , 1997, pages 4539-4540, vol. 62.	
LH	AZ	MASQUELIN, et al., "A New General Three Component Solution-Phase Synthesis of 2-Amino-1, 3-Thiazole and 2,4-Diamino-1,3-Thiazole Combinatorial Libraries" <i>Tetrahedron</i> , 2001, pages 153-156, vol. 57.	
LH	BA	NGUYEN, et al., "7SK Small Nuclear RNA Binds to and Inhibits the Activity of CDK9/Cyclin T Complexes" <i>Nature (London)</i> , 2001, pages 322-325, vol. 414.	
LH	BB	PATANI, et al., "Bioisosterism: A Rational Approach in Drug Design" <i>Chem. Rev.</i> , 1996, pages 3147-3176, vol. 96.	
LH	BC	RAJASEKHARAN, et al., "Studies on the Synthesis of 5-Acyl-2,4-Diaminothiazoles From Amidinothioureas" <i>Synthesis</i> , 1986, pages, 353-355.	
LH	BD	RAO, et al., "Cyclin-Dependent Kinases and Their Small-Molecule Inhibitors in Cancer Therapy", <i>Targets Cancer Chemothe.</i> , 2002, pages 145-178.	
LH	BE	SCHANG, et al., "Roscovitine, a Specific Inhibitor of Cellular Cyclin-Dependent Kinases, Inhibits Herpes Simplex Virus DNA Synthesis in the Presence of Viral Early Proteins" <i>J. Virol.</i> , 2000, pages 2107-2120, vol. 74.	
	BF	STILL, et al., "Rapid Chromatographic Technique for Preparative Separations with Moderate Resolution" <i>J. Org. Chem.</i> , 1978, page 2923, vol. 43.	
LH	BG	TANIGUCHI, et al., "Induction of the p16 ^{INK4a} Senescence Gene as a New Therapeutic Strategy for the Treatment of Rheumatoid Arthritis" <i>Nat. Med.</i> , 1999, pages 760-767, vol. 5.	
LH	BH	TOLDEDO, et al., "The Structure-Based Design of ATP-Site Directed Protein Kinase Inhibitors" <i>Curr. Med. Chem.</i> , 1999, pages 775-805, vol. 6.	

EXAMINER:


DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or no citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901-04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Mail Stop: DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO



INFORMATION DISCLOSURE STATEMENT BY APPLICATION

(Use as many sheets as necessary)

Complete if Known

Application Number	10/631,358
Filing Date	July 30, 2003
First Named Inventor	David Kucera
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	PC19184 (AG0184)

LI	BI	YANG, et al., "The 7SK Small Nuclear RNA Inhibits the CDK9/Cyclin T1 Kinase to Control Transcription" <i>Nature (London)</i> , 2001, pages 317-322, vol. 414.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or no citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). 2See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901-04. 3Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Mail Stop: DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.